Table 2.
Gene | Forward | Reverse |
---|---|---|
ACTA2 | 5′-AATGGCTCTGGGCTCTGTAA-3′ | 5′-TTTTGCTCTGTGCTTCGTCA-3′ |
FGFR1 | 5′-GGGCTGGAATACTGCTACAA-3′ | 5′-GCCAAAGTCTGCTATCTTCATC-3′ |
FGFR2 | 5′-GGATAACAACACGCCTCTCTT-3′ | 5′-GCCCAAAGCAACCTTCTC-3′ |
FGFR3 | 5′-TGGTGTCCTGTGCCTACC-3′ | 5′-CCGTTGGTCGTCTTCTTGT-3′ |
FGFR4 | 5′-AACCGCATTGGAGGCATT-3′ | 5′-TCTACCAGGCAGGTGTATGT-3′ |
GAPDH | 5′-GAAGGTCGGAGTCAACGGATT-3′ | 5′-TGACGGTGCCATGGAATTTG-3′ |
IL1 β | 5′-GTGGCAATGAGGATGACTTG-3′ | 5′-GTGGTGGTCGGAGATTCGTA-3′ |
IL6 | 5′-TGTGTGGGTCTGTTGTAGGG-3′ | 5′-CCCGTGCAATATCTAGGAAAA-3′ |
IL8 | 5′-TGTGTGGGTCTGTTGTAGGG-3′ | 5′-CCCGTGCAATATCTAGGAAAA-3′ |
INFγ | 5′-GCAGGTCATTCAGATGTAGCGG-3′ | 5′-CCACACTCTTTTGGATGCTCTGG-3′ |
MCP1 | 5′-CTCAGCCAGATGCAATCAA-3′ | 5′-CACTTCTGCTTGGGGTCA-3′ |
NLRP3 | 5′-GGACTGAAGCACCTGTTGTGCA-3′ | 5′-TCCTGAGTCTCCCAAGGCATTC-3′ |
RLBP1 | 5′-GCTGCTGGAGAATGAGGAAA-3′ | 5′-TGGTGGATGAAGTGGATGG-3′ |
S100A4 | 5′-CCTGGATGTGATGGTGTCC-3′ | 5′-TCGTTGTCCCTGTTGCTGT-3′ |
TNFα | 5′-TGCTTGTTCCTCAGCCTCTT-3′ | 5′-GCTTGTCACTCGGGGTTC-3′ |
VEGF-A | 5′-AATCGAGACCCTGGTGGAC-3′ | 5′-GGTGAGGTTTGATCCGCATA-3′ |
VEGFR1 | 5′-AGCAGTTCCACCACTTTAGA-3′ | 5′-GAACTTTCCACAGAGCCCTT-3′ |
VEGFR2 | 5′-GGAAATGACACTGGAGCCTA-3′ | 5′-TTTGAAATGGACCCGAGACA-3′ |
VEGFR3 | 5′-CAACGACCTACAAAGGCTCT-3′ | 5′-GTAAAACACCTGGCCTCCTC-3′ |
VIM | 5′-CGCCAGATGCGTGAAATG-3′ | 5′-ACCAGAGGGAGTGAATCCAGA-3′ |
Abbreviations.ACTA2: actin α 2; FGFR: fibroblast growth factor receptor; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; IL: interleukin; INFγ: interferon γ; MCP1: monocyte chemoattractant protein 1; NLRP3: nucleotide-binding oligomerization domain (NOD), leucine-rich repeat (LRR)-containing proteins 3; RLBP1: retinaldehyde-binding protein 1; S100A4: S100 calcium-binding protein A4; TNFα: tumor necrosis factor α; VEGF-A: vascular endothelial growth factor-A; VEGFR: vascular endothelial growth factor receptor; VIM: vimentin.